Patisiran Promising for Transthyretin-Mediated Amyloidosis With Cardiomyopathy
The APOLLO-B study included patients 18 years of age and older with ATTR amyloidosis (hereditary or wild-type) with cardiomyopathy.
The APOLLO-B study included patients 18 years of age and older with ATTR amyloidosis (hereditary or wild-type) with cardiomyopathy.
Eplontersen is an investigational ligand-conjugated antisense medicine designed to reduce the production of TTR protein to treat both hereditary and nonhereditary forms of ATTR.
Imcivree is a melanocortin 4 receptor (MC4R) agonist that re-establishes MC4 receptor pathway activity to reduce hunger and promote weight loss.
Vutrisiran is an investigational, subcutaneously-administered RNAi therapeutic designed to block the production of wild-type and mutant transthyretin protein.
Omaveloxolone is an investigational Nrf2 activator.
The approval was based on data from a phase 3 study that compared Cuvrior with penicillamine in 53 adults with Wilson disease.
PXL770 is a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator.
Nonalcoholic fatty liver disease often has several systemic comorbities, including obstructive sleep apnea. Researchers explored a psychological link between them.
Galactosemia is a rare genetic metabolic disease caused by an inability to metabolize galactose.
Approximately 5% to 10% of shift workers, including many health care professionals, suffer from shift work disorder, a circadian sleep-wake cycle disorder defined by poor quality sleep.